PFE - Pfizer Inc.
| Previous Close | 39.88 |
| Open | 39.93 |
| Bid | 38.50 x 4000 |
| Ask | 0.00 x 1000 |
| Day's Range | 38.42 - 39.93 |
| 52 Week Range | 34.37 - 46.47 |
| Volume | 47,988,381 |
| Avg. Volume | 24,613,119 |
| Market Cap | 218.63B |
| Beta (3Y Monthly) | 0.59 |
| PE Ratio (TTM) | 21.10 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.44 (3.39%) |
| Ex-Dividend Date | 2019-01-31 |
| 1y Target Est | N/A |
- Motley Fool•3 days ago
5 Top Pharmaceutical Stocks to Buy in 2019
Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.
- Investopedia•3 days ago
The Top 10 Biotechnology Companies (JNJ, ROG.VX)
Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.
- MarketWatch•3 days ago
Pfizer, Lilly shares decline as osteoarthritis drug misses goals in study
Shares of drug makers Pfizer Inc. and Eli Lilly & Co. declined in the extended session Thursday after the companies said a clinical study of an osteoarthritis drug didn't meet certain goals. Pfizer shares declined 1% after hours, following a 1.3% decline to close at $39.38 in the regular trading session. Lilly shares fell 1.9% after hours, following a 1.1% close lower at $115.20. The companies said that a late-stage study of their drug tanezumab at 5 mg did not show a statistically significant improvement in overall osteoarthritis symptoms compared with nonsteroidal anti-inflammatory drugs. A 2.5 mg dose did not show a statistically significant improvement in pain, physical function or patients' overall assessment, the companies said. "We are analyzing these findings in the context of the recent Phase 3 results as we assess potential next steps for tanezumab," said Ken Verburg, Pfizer's tanezumab development team leader, in a statement. "We plan to review the totality of data from our clinical development program for tanezumab with regulatory authorities."
- Reuters•4 days ago
Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study
A lower dose of non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, the companies said on Thursday. The drug, tanezumab, belongs to a new category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and has been touted as a potential blockbuster. The study tested the treatment in two doses, 2.5 mg and 5 mg, comparing the long-term joint safety and effectiveness at the end of 16 weeks with painkillers that are normally prescribed to patients.
- Zacks•4 days ago
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Pfizer (PFE) closed at $39.38 in the latest trading session, marking a -1.25% move from the prior day.
- Bloomberg•4 days ago
Worsening Health-Care Rout Wipes Out $150 Billion in Four Days
About $150 billion of market value was erased from companies in the S&P 500 Health Care Index in the four days through Thursday, when markets closed for the holiday weekend. “This is third-worst that I’ve seen probably in the last 10 years,” Christian Fay, who helps manage $3.6 billion at BNP Paribas Asset Management, said in a telephone interview.
- ETF Trends•4 days ago
Pharmaceutical ETFs Catch Healthcare Contagion
The retreat in healthcare stocks is bleeding over, with areas like pharmaceutical sector exchange traded funds being dragged down by association. The iShares U.S. Pharmaceuticals ETF (IHE) continued its downward spiral Thursday, falling 0.4%. “Clearly, huge stock impacts to HCA and managed care can’t be ignored and ‘collateral damage’ to sub-sectors like biopharma in the following days are reflective of a view that mutual funds are drawing down and souring” on health care, Jefferies analyst Michael Yee wrote in a note, according to Bloomberg.
- Zacks•4 days ago
Clovis Focuses on Rubraca Label Expansion, Competition Stiff
Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.
- Zacks•4 days ago
Can Q1 Earnings Lift Healthcare ETFs Higher?
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
- Zacks•4 days ago
Here Are the Key Takeaways From J&J's Q1 Earnings Report
Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.
- Zacks•5 days ago
Wave Life Sciences Plunges After DMD Study Data Readout
Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.
- Investing.com•5 days ago
Pfizer Falls 3%
Investing.com - Pfizer (NYSE:PFE) fell by 3.02% to trade at $39.69 by 13:51 (17:51 GMT) on Wednesday on the NYSE exchange.
- InvestorPlace•6 days ago
5 Healthcare Stocks to Watch If America Chooses a Single-Payer System
Even for the brightest among us, our current healthcare system is a convoluted mess that's difficult to fully understand. With terms like HMOs, PPOs and PFPMs, searching for the right coverage is often as desirable as doing your taxes. However, a political movement to simplify the system has serious implications for you and your portfolio (via healthcare stocks).Earlier this week, Senator Bernie Sanders explained his ambitious plan for a single-payer healthcare system. Broadly, what this entails is that all Americans will enjoy comprehensive health coverage. Under his "Medicare for All Act," patients won't have to pay out of pocket for doctor visitations. It has raised eyebrows because the proposal is considerably more generous than other single-payer countries.Even more startling for both supporters and opponents, Sanders' plan has generated significant support. In particular, presidential candidates Elizabeth Warren, Cory Booker, Kamala Harris and Kirsten Gillibrand cosponsored the bill. With momentum rising, so too has the importance for healthcare stocks to watch.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOne of the striking components of Sanders' plan is its scope. If it passes, all invoices will eventually go to the federal government. Theoretically, this approach does away with some of the volatile pricing imposed within the current system. But such pricing changes would severely impact healthcare stocks.Another sticking point regarding this comprehensive proposal is a possible existential crisis. In many ways, healthcare stocks exist because our broader medical umbrella is so convoluted. Plus, pharmaceuticals can radically hike drug prices, knowing that insurers and patients have little recourse. * 7 Stocks to Buy for Spring Season Growth Of course, paying for a new system would require a substantial tax influx. Sanders hasn't provided a convincing financial plan to accommodate his bill. Nevertheless, the current political environment suggests a change is coming. Here are five healthcare stocks to watch, just in case. UnitedHealth Group (UNH)Source: Shutterstock On Thursday, shares of UnitedHealth Group (NYSE:UNH) tumbled over 4%, and I can't say that I'm surprised. Sure, the commonly cited explanation for why UNH stock took a hit was an analyst downgrade. But the reality is that among healthcare stocks to watch, insurance providers suffer the most risk.Naturally, the Medicare for All Act weighs heavily on UNH stock. Insurers thrive on both the complexity of our healthcare system and the necessity for it. Going without insurance just isn't smart, considering the likelihood of a catastrophic event or disease. According to a shocking BBC report last year, cancer is rising everywhere, including in developed nations.Moreover, fighting that awful disease isn't cheap, with average treatments running well into six digits. The threat of financial ruin is enough for people to run to insurance companies. But with government-endorsed mandated coverage, it's unclear how for-profit insurers like UNH stock can thrive. Cigna (CI)Source: Shutterstock Also on Thursday, shares of Cigna (NYSE:CI) fell sharply, losing 2.5%. Again, I'm not surprised. Compared to other healthcare stocks to watch, CI stock faces an existential threat. If the Medicare for All Act passes, it has severe implications for the insurance company.As we discussed, Sanders' plan is incredibly comprehensive. In his vision of a covered America, no one reaches into their wallets. Whether you're seeing a doctor, getting your teeth cleaned at the dentist's office, or trying on a new pair of eyeglasses, sticker shock in this arena will be obsolete. * 10 S&P 500 Stocks to Weather the Earnings Storm Of course, the problem is that CI stock thrives on this sticker shock. When you cut through all the corporate BS, you realize that the insurance industry prospers on fear. But a government-mandated coverage plan eliminates that fear with a safety net. Thus, I'm currently hesitant on Cigna, and other insurance-related healthcare stocks. Pfizer (PFE)Source: Kojach Via FlickrAlthough insurance companies present an easy target in light of recent political developments, pharmaceuticals can't dodge the bullet, either. Investors and especially current shareholders of Pfizer (NYSE:PFE) should adopt a very cautious stance. On Thursday, PFE stock dipped more than 1%.As with the first two healthcare stocks to watch, Pfizer's pensive trading isn't surprising. In prior generations, a rising tide lifted all boats. But in the next few years, a receding tide could strand everyone. That might be the case for PFE stock, and similar rivals in the pharmaceutical space.As the controversy surrounding the "pharma bro" incident revealed, pharmaceuticals can get away with charging ridiculous prices. But with the Medicare for All Act, that type of predatory behavior -- or even robust capitalism -- stops. When you have to answer to the federal government, suddenly, everyone plays nice.That's great for patients, but not so much for PFE stock. Boston Scientific (BSX)Source: Boston Scientific Ordinally, I wouldn't issue a cautionary note on Boston Scientific (NYSE:BSX). As one of the world's premiere medical-equipment providers, BSX stock represents a life-saving investment. Plus, shares have generally performed well following the aftermath of the Great Recession.Unfortunately, that might change in the coming years, especially if the Medicare for All Act passes. Similar to the plight of other medical stocks to watch, Boston Scientific absorbed a noticeable 1% decline on Thursday. That's just the beginning if the worst-case scenario occurs. * 10 Dividend Growth Stocks You Can't Miss Primarily, BSX stock will essentially lose out on a free market. Instead, a government-imposed network will dictate product pricing and other core details. Essentially, this eliminates the profit motive for Boston Scientific. Since many developed countries have some sort of single-payer system, BSX must cope with the loss of a viable partner. HCA Healthcare (HCA)Source: Shutterstock On surface level, HCA Healthcare (NYSE:HCA) should be one of the healthcare stocks to watch…for a positive reason. Following the end of the Obama administration, Gallup reported a conspicuous rise in the number of uninsured Americans. But under Medicare for All, the insured will likely represent a surge in demand for HCA stock.That's a strong benefit, but it's probably not a net benefit. I say this because the markets really punished HCA stock on Thursday, dropping it down nearly 3%. The most common explanation is that the rest of the sector was also volatile. If other segments within the healthcare industry falls, so too will HCA.But the overriding factor behind the single-payer proposal is big government. So even if the uninsured flock to hospitals and clinics, they can't adopt capitalistic pricing. Instead, the feds will oversee everything, ensuring everyone has access to equal and "fair" healthcare.It's a great deal for patients, but not so much for hospitals, or anyone in this industry for that matter.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * FAANNG Stocks, Ranked From Cheapest to Most Expensive * 7 Stocks With a Lot on the Line This Earnings Season * 7 Marijuana Companies: Which Pot Stocks Should You Buy? Compare Brokers The post 5 Healthcare Stocks to Watch If America Chooses a Single-Payer System appeared first on InvestorPlace.
- Zacks•6 days ago
J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.
- CNBC•7 days ago
These 2 health-care giants could take down the ETFs in their sector, says investor
Health-care stocks are under pressure, and the sector's fate rests on two of the space's most well-known names, says one expert.
- American City Business Journals•7 days ago
Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's
The South San Francisco company is putting its IPO where its mouth is — hoping to take its lead drug, targeting a tooth-loss-causing bacteria that migrates from the mouth to the brain, into a Phase II/III clinical trial soon.
Market Realist•7 days agoAnalyzing Recent Regulatory Approvals for Pfizer’s Oncology Drugs
Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Lorbrena’s approvalOn November 2, Pfizer (PFE) issued a press release announcing the FDA’s approval of Lorbrena, a third-generation TKI (tyrosine kinase
- Zacks•7 days ago
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer
FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Market Realist•7 days agoXtandi: A Key Oncology Pillar in 2019
Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Xtandi’s growth trends According to Pfizer’s (PFE) fourth-quarter earnings conference call, Xtandi is a pillar of the company’s oncology business. In 2018, Pfizer
- Market Realist•7 days ago
Why Ibrance Is a Major Growth Driver for Pfizer
Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Recent Ibrance approval On April 4, Pfizer (PFE) issued a press release announcing the FDA’s approval of its leading CDK4/6 (cyclin-dependent kinase 4/6) inhibitor
- Motley Fool•8 days ago
The 3 Greatest Risks Pfizer Faces
Here's what could get in the way of the big pharma company's future success.
- Market Realist•10 days ago
PFE or AZN: Comparing Their Earnings Growth in 2019
Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Earnings guidance On its fourth-quarter earnings conference call, Pfizer (PFE) said that it expected its 2019 adjusted diluted EPS to be $2.82–$2.92, which doesn’t
- Market Realist•10 days ago
What Are Analysts Recommending for PFE and AZN?
Pfizer or AstraZeneca: Which Is a Better Pick in April?Stock price movementsOn April 11, Pfizer (PFE) closed at $42.27, 1.08% lower than its previous closing price, 22.99% higher than its 52-week low of $34.37, and 9.04% below its 52-week high of
- Zacks•10 days ago
Dow 30 Stock Roundup: Procter & Gamble Hikes Dividend, Boeing Q1 Commercial Deliveries Fall
The index traversed a lackluster trading week as investors looked toward first-quarter earnings numbers for direction.
- InvestorPlace•10 days ago
Forward Guidance Will Make or Break JNJ Earnings
Johnson & Johnson (NYSE:JNJ) announces earnings on Tuesday before market open. The New Brunswick, New Jersey-based healthcare company has become one of the strongest, longest-running brands in existence.Source: Shutterstock However, challenges with drug patent expirations have blunted earnings growth in JNJ stock. This has left JNJ trading in a range for more than two years. Though this report will probably not deliver any meaningful surprises, investors still need signs that earnings growth will resume in Johnson & Johnson stock to break the equity out of its range. Pharma Will Drive the Report on JNJ StockTuesday's announcement will kick off earnings season for the pharma industry. Wall Street forecasts Q1 earnings to come in at $2.06 per share, matching the number for Q1 2018. They also predict revenues of $19.6 billion, a 2% decrease from the $20.01 billion announced in the same quarter last year.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 8 Risky Stocks to Watch as Earnings Season Kicks Off Consumers know JNJ best for its consumer health products. However, many often forget that medical devices and pharma each drive greater shares of the company's revenue. It is pain in the pharma division that's driving the predicted revenue decline.Sales of Simponi/Simponi Aria and Xarelto fell in the fourth quarter. The company has also cited alternatives to Velcade, Tracleer and Zytiga in explaining revenue declines. By no means is JNJ stock the only pharma stock to struggle with new competition. AbbVie (NYSE:ABBV) faces the same issue with Humira. Also, Pfizer (NYSE:PFE) will see its patent protection go away in its blockbuster drug Lyrica this summer.Patent expirations have long affected pharma stocks, and this may have helped to trap JNJ stock in a range. Since early 2017, JNJ stock has traded near the $120 per share to $150 per share range. Now, its forward P/E ratio comes in below 15. In the past few years, JNJ's forward P/E has typically been in the high teens to the low 20s.The stagnant earnings may explain the modest discount in JNJ stock. For this reason, I think investors will focus on guidance in the upcoming report. As of now, Wall Street expects 2019 earnings to increase by 4.6%. In all likelihood, investors will need to at least see that figure to move JNJ higher. JNJ Stock Retains Numerous AdvantagesFortunately, some tailwinds could help JNJ stock. Traders should remember that JNJ stock usually beats estimates, at least on earnings. For that reason, I would expect the earnings number to come in higher than $2.06 per share.Also, JNJ stock should continue to deliver the stability for which the public knows the company. For now, JNJ and Microsoft (NASDAQ:MSFT) are the only two U.S. companies that maintain a AAA credit rating. Debt levels have fallen over the last year, so I see no change in that status coming.Also, attention should shift back to the dividend in the coming days. The company traditionally announces a hike to its JNJ stock dividend soon after the Q1 report. They have increased the payout every year since 1963. Hence, I do not see the company breaking its 56-year streak of payout increases. The only question remains how much of a dividend hike JNJ gives.Johnson & Johnson stock currently pays 90 cents per share each quarter, a yield of about 2.65%. In the past, earnings growth has had little obvious effect on the size of the increase. While I do not foresee any surprises, the dividend boost could help JNJ stock to recover. Concluding Thoughts on JNJ StockGoing into earnings, investors need to see guidance that will help break JNJ stock out of its range. Johnson & Johnson usually beats earnings. However, patent expirations on key drugs have led to modest declines in revenue. They may also explain why JNJ has traded in a range for the last two years.However, conditions increasingly point to the potential for a rising stock price. The P/E ratio has fallen below company averages. Moreover, analysts forecast earnings increases in later quarters and for the overall year. If company guidance confirms those predictions, JNJ stock should rise. An expected dividend hike in the coming weeks should offer further help. * 7 AI Stocks to Watch with Strong Long-Term Narratives JNJ stock trades at about $135 per share now. If guidance affirms or exceeds profit growth predictions, I think it could help take JNJ past $150 per share sooner rather than later.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * FAANNG Stocks, Ranked From Cheapest to Most Expensive * 7 Stocks With a Lot on the Line This Earnings Season * 7 Marijuana Companies: Which Pot Stocks Should You Buy? Compare Brokers The post Forward Guidance Will Make or Break JNJ Earnings appeared first on InvestorPlace.
